Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPCX
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
CTRA
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.69% |
| 2 | Industrials | 9.96% |
| 3 | Consumer Discretionary | 8.03% |
| 4 | Healthcare | 7.46% |
| 5 | Financials | 6.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HIVE
2676
HIVE Digital Technologies
HIVE
$831M
| $243K | ﹤0.01% |
+66,726
| New | +$216K |
|
2677
Compass Diversified
CODI
$879M
| $242K | ﹤0.01% |
+22,667
| New | +$247K |
|
2678
Boston Beer
SAM
$1.91B
| $241K | ﹤0.01% |
1,362
-336
| -20% | -$68.2K |
|
2679
Cytek Biosciences
CTKB
$625M
| $241K | ﹤0.01% |
+54,381
| New | +$232K |
|
2680
Donegal Group Class A
DGICA
$693M
| $239K | ﹤0.01% |
+12,646
| New | +$220K |
|
2681
PUT
Cintas
CTAS
$81.6B
| $238K | ﹤0.01% |
1,400
-4,200
| -75% | -$726K |
|
2682
PUT
Coherent
COHR
$56.7B
| $237K | ﹤0.01% |
+600
| New | +$212K |
|
2683
Astec Industries
ASTE
$1B
| $236K | ﹤0.01% |
3,862
-6,937
| -64% | -$383K |
|
2684
Fox Class A
FOXA
$28.8B
| $236K | ﹤0.01% |
4,525
-649,502
| -99% | -$40.1M |
|
2685
CALL
American Airlines Group
AAL
$9.15B
| $235K | ﹤0.01% |
13,000
-237,000
| -95% | -$3.17M |
|
2686
PUT
Direxion Daily FTSE China Bull 3X ETF
YINN
$707M
| $234K | ﹤0.01% |
+10,900
| New | +$345K |
|
2687
Kearny Financial
KRNY
$612M
| $233K | ﹤0.01% |
+24,669
| New | +$203K |
|
|
DVLT
2688
Datavault AI
DVLT
$272M
| $231K | ﹤0.01% |
659,642
+558,955
| +555% | +$306K |
|
2689
PUT
TG Therapeutics
TGTX
$8.31B
| $231K | ﹤0.01% |
+4,200
| New | +$172K |
|
|
ARDT
2690
Ardent Health
ARDT
$1.55B
| $230K | ﹤0.01% |
23,424
-20,451
| -47% | -$194K |
|
2691
Danaos Corp
DAC
$2.73B
| $230K | ﹤0.01% |
+1,877
| New | +$234K |
|
2692
Peoples Bancorp
PEBO
$1.44B
| $229K | ﹤0.01% |
5,971
-17,566
| -75% | -$612K |
|
2693
Telkom Indonesia
TLK
$14.8B
| $229K | ﹤0.01% |
+17,024
| New | +$283K |
|
2694
PubMatic
PUBM
$747M
| $228K | ﹤0.01% |
17,416
-19,989
| -53% | -$208K |
|
2695
Duos Technologies
DUOT
$324M
| $228K | ﹤0.01% |
19,039
-307,435
| -94% | -$3.09M |
|
|
UROY
2696
Uranium Royalty Corp
UROY
$1.67B
| $227K | ﹤0.01% |
+81,700
| New | +$286K |
|
|
QCLS
2697
Q/C Technologies Inc
QCLS
$21.1M
| $225K | ﹤0.01% |
+57,692
| New | +$223K |
|
2698
NewtekOne
NEWT
$362M
| $225K | ﹤0.01% |
+15,159
| New | +$200K |
|
2699
Boston Omaha
BOC
$426M
| $224K | ﹤0.01% |
16,436
+1,704
| +12% | +$21.4K |
|
2700
Forestar Group
FOR
$1.49B
| $224K | ﹤0.01% |
+7,081
| New | +$195K |
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $7.14B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 9.7% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.